Kidney fibrosis is a critical health problem in the United States because it represents the final common pathway of all chronic kidney diseases yet no biomarkers exist to aid in its diagnosis or measurement of progression. Using cutting edge genomic techniques, we have identified six novel biomarkers of kidney fibrosis and we hypothesize that levels of these biomarkers will accurately reflect kidney fibrosis in humans. In this proposal we have assembled three unique human patient cohorts in which to evaluate these six biomarkers, using histologic kidney fibrosis from kidney biopsy as the gold standard. We will measure biomarker levels in both serum and urine, using controlled and validated assays, and compare biomarker levels with the degree of tubulointerstitial fibrosis observed histologically. The most promising biomarkers will then be measured in a prospective chronic kidney disease cohort, comparing rapid progressors with those who do not progress. Our multidisciplinary team includes individuals with expertise in preclinical fibrosis models, assay development, molecular biology, regulatory compliance, clinical epidemiology, trial design and biostatistics. Together, the proposed experiments represent a rigorous evaluation of these six biomarkers in human chronic kidney disease and will pave the path forward for future studies that will transform clinical trial design and care in nephrology.

Public Health Relevance

Kidney fibrosis is the leading cause of kidney failure worldwide and represents an enormous health burden and unmet medical need. New biomarkers are needed to quantify kidney fibrosis non-invasively in order to identify patients at risk of kidney disease progression and to facilitate clinical trial design. We have discovered six novel biomarkers of kidney fibrosis that are extremely promising for measurement of kidney fibrosis in humans. The experiments in this application are designed to evaluate these six biomarkers in three unique patient cohorts in order to define the biomarker with the greatest promise for future large scale qualification efforts, ideally in collaboration with NIH, regulatory agencies, and industry.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01DK104308-01
Application #
8824765
Study Section
Special Emphasis Panel (ZDK1-GRB-S (O5))
Program Officer
Flessner, Michael Francis
Project Start
2014-09-24
Project End
2019-06-30
Budget Start
2014-09-24
Budget End
2015-06-30
Support Year
1
Fiscal Year
2014
Total Cost
$397,480
Indirect Cost
$172,862
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115